--- title: "Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 at BTIG Research" type: "News" locale: "en" url: "https://longbridge.com/en/news/295134363.md" description: "BTIG Research raised its price target for Delcath Systems (NASDAQ:DCTH) from $17.00 to $21.00, maintaining a 'buy' rating. This indicates a potential 40% upside. Other firms like Zacks and Weiss also recently adjusted their ratings. The stock rose 18.8% on Thursday, with institutional investors increasing holdings. Analysts anticipate an EPS of -0.88 for the current year." datetime: "2026-08-06T19:00:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295134363.md) - [en](https://longbridge.com/en/news/295134363.md) - [zh-HK](https://longbridge.com/zh-HK/news/295134363.md) generator: "portal-rs" --- # Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 at BTIG Research Delcath Systems (NASDAQ:DCTH - Get Free Report) had its price target raised by analysts at BTIG Research from $17.00 to $21.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's price objective indicates a potential upside of 40.00% from the company's current price. Get **Delcath Systems** alerts: A number of other research firms have also recently issued reports on DCTH. Zacks Research upgraded Delcath Systems from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 7th. Weiss Ratings upgraded Delcath Systems from a "sell (d)" rating to a "sell (d+)" rating in a research note on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $22.83. **Get Our Latest Stock Analysis on DCTH** ## Delcath Systems Stock Up 18.8% Shares of NASDAQ:DCTH traded up $2.37 during trading on Thursday, hitting $15.00. 2,244,794 shares of the company were exchanged, compared to its average volume of 462,732. The business's 50 day moving average is $12.18 and its 200-day moving average is $10.81. The company has a market capitalization of $517.83 million, a P/E ratio of 1,497.00 and a beta of 0.52. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $15.62. Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.16. The firm had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. As a group, sell-side analysts anticipate that Delcath Systems will post -0.88 earnings per share for the current year. ## Institutional Investors Weigh In On Delcath Systems Institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System bought a new stake in Delcath Systems during the 2nd quarter worth approximately $26,000. Russell Investments Group Ltd. bought a new position in shares of Delcath Systems in the third quarter valued at approximately $29,000. Tower Research Capital LLC TRC bought a new position in shares of Delcath Systems in the second quarter valued at approximately $40,000. Legal & General Group Plc purchased a new position in shares of Delcath Systems during the second quarter valued at approximately $46,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Delcath Systems during the second quarter valued at approximately $151,000. Institutional investors and hedge funds own 61.12% of the company's stock. ## Delcath Systems Company Profile (Get Free Report) Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company's core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma. ## Read More - Five stocks we like better than Delcath Systems - Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling - 4 Oil and Gas ETF Plays as Prices Stay Sky-High - What Tesla Stands to Lose If It Walks Away From China - Disney Sets Up for a Magical Year in 2027 *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Delcath Systems Right Now? Before you consider Delcath Systems, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list. While Delcath Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [DCTH.US](https://longbridge.com/en/quote/DCTH.US.md) - [LGEN.UK](https://longbridge.com/en/quote/LGEN.UK.md) - [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md) - [TSLA.US](https://longbridge.com/en/quote/TSLA.US.md) - [DIS.US](https://longbridge.com/en/quote/DIS.US.md) ## Related News & Research - [Renaissance Technologies LLC Trims Position in Delcath Systems, Inc. $DCTH](https://longbridge.com/en/news/295766216.md) - [Algert Global LLC Has $2.83 Million Position in Adaptive Biotechnologies Corporation $ADPT](https://longbridge.com/en/news/297395406.md) - [BTIG Keeps Their Buy Rating on Shift4 Payments (FOUR)](https://longbridge.com/en/news/297163377.md) - [Inside Autodesk's Stock Dip: Surging Cloud Sales Beat Estimates, But Cost Outlook Weighs](https://longbridge.com/en/news/297357734.md) - [Nantahala Capital Management LLC Buys Shares of 763,446 Forrester Research, Inc. $FORR](https://longbridge.com/en/news/297400557.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**